Diaceutics (LON:DXRX) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Diaceutics (LON:DXRX) in a research note released on Tuesday morning, Marketbeat Ratings reports. The firm currently has a GBX 160 ($2.03) price objective on the stock.

Diaceutics Price Performance

Diaceutics stock opened at GBX 124 ($1.58) on Tuesday. Diaceutics has a 12 month low of GBX 84.50 ($1.07) and a 12 month high of GBX 136 ($1.73). The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92. The business has a 50 day simple moving average of GBX 122.28 and a 200-day simple moving average of GBX 126.30. The stock has a market capitalization of £104.74 million, a PE ratio of -4,066.67 and a beta of 0.58.

Diaceutics Company Profile

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.